Filing Details

Accession Number:
0001181431-13-045320
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-08-16 16:56:28
Reporting Period:
2013-08-14
Filing Date:
2013-08-16
Accepted Time:
2013-08-16 16:56:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1338042 Aegerion Pharmaceuticals Inc. AEGR Pharmaceutical Preparations (2834) 202960116
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1520265 J. Mark Fitzpatrick C/O Aegerion Pharmaceuticals, Inc.
101 Main Street, Suite 1850
Cambridge MA 02142
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-08-14 7,500 $17.64 8,000 No 4 M Direct
Common Stock Disposition 2013-08-14 2,512 $92.74 5,488 No 4 S Direct
Common Stock Disposition 2013-08-14 4,400 $93.71 1,088 No 4 S Direct
Common Stock Disposition 2013-08-14 588 $94.44 500 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2013-08-14 7,500 $0.00 7,500 $17.64
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
212,500 2021-06-01 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Plan"). The Plan was adopted for purposes of investment portfolio diversification.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.10 to $93.09, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.14 to $94.10, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.18 to $94.98, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  5. 132,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on June 1, 2011. 88,000 of the shares of common stock underlying this stock option vest over four years in equal monthly installments starting on the date of marketing approval for Lomitapide by the Food and Drug Administration.